# Voriconazole vs. Amphotericin B in the Treatment of Invasive Aspergillosis

> **NCT00001646** · PHASE3 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 10 (—)

## Conditions studied

- Acquired Immunodeficiency Syndrome
- Aspergillosis
- HIV Infections
- Immunologic Deficiency Syndromes
- Neutropenia

## Interventions

- **DRUG:** Voriconazole
- **DRUG:** Amphotericin B

## Key facts

- **NCT ID:** NCT00001646
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1997-08
- **Primary completion:** —
- **Final completion:** 2000-08
- **Target enrollment:** 10 (—)
- **Last updated:** 2008-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00001646

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00001646, "Voriconazole vs. Amphotericin B in the Treatment of Invasive Aspergillosis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00001646. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*